Sanofi (SNY -0.8%) subsidiary Genzyme says the FDA has accepted for review its supplemental...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY -0.8%) subsidiary Genzyme says the FDA has accepted for review its supplemental Biologics License Application seeking approval of Lemtrada for the treatment of relapsing multiple sclerosis. Genzyme expects FDA action on the application in H213.